Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB018A in Active Moderate to Severe Thyroid Eye Disease
NCT07622108Phase 3Recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 3 trial of MHB018A in thyroid eye disease (TED), sponsored by Minghui Pharmaceutical, Inc.. Started Sep 2026; status: recruiting.
02
Drugs
MHB018A
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07622108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622108.